attack
-
FDA approves Shire’s FIRAZYR for acute attacks of hereditary angioedema
Shire plc announced that the US Food and Drug Administration (FDA) has granted marketing approval for FIRAZYR (icatibant injection) for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. “Until now, HA…
attack | 25 August 2011
-
Angina Drug Reduces Incidences of Heart Attack
Findings in patients with angina who participated in the Beautiful study, show that there is a 42 percent reduction in heart attack with Procoralan (ivabradine). This benefit was particularly marked in patients with a resting heart rate >= 70 beats p…
attack | 18 September 2009
-
Prasugrel, Clopidogrel head-to-head study
A new, pre-specified analysis of the landmark Phase III head-to-head Triton-Timi 38 study showed certain patients were 35% less likely to have a recurrent event (composite endpoint of heart attack, stroke or cardiovascular death) than those who took …
attack | 25 August 2008
-
Reducing the risk of heart attack and stroke in patients with diseases
Pfizer Inc says in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 35% compared with Li…
attack | 11 August 2008
-
Study: C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal And Facial Attacks In Patients With Hereditary Angioedema
C1-esterase inhibitor (C1-INH) concentrate is a safe and effective therapy that rapidly relieves acute abdominal and facial swelling attacks in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presente…
attack | 08 April 2008
